Bellerophon Announces Initial Data From Acute Hemodynamic Dose Escalation Study Of Inopulse For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease; Results 'clinically meaningful improvements' In Pre-Specified Parameters

The results to date from PHPF-002 have demonstrated clinically meaningful improvements in multiple pre-specified pulmonary hemodynamic parameters, starting with the lowest dose of 30 mcg/kg IBW/hr (iNO30). Dose

Benzinga · 11/12/2019 13:38

The results to date from PHPF-002 have demonstrated clinically meaningful improvements in multiple pre-specified pulmonary hemodynamic parameters, starting with the lowest dose of 30 mcg/kg IBW/hr (iNO30). Dose escalation showed:

  • Pulmonary vascular resistance (PVR) improved by 29% (baseline PVR was 584 dynes × sec × cm-5)
  • Cardiac Output (CO) improved by 16% (baseline CO was 3.5 L/min)
  • Mean Pulmonary Arterial Pressure (mPAP) improved by 10% across doses (baseline mPAP was 34.3 mmHg)
  • Oxygen saturation remained stable across doses
  • iNO was well-tolerated with no safety concerns across doses